Mologen AG (MOLGF.PK) Expands Its Executive Board by Chief Medical Officer
3/26/2013 12:08:42 PM
More...
|
Mologen AG (MOLGF.PK): Research and Financing Successes in the 2012 Financial Year
3/21/2013 12:31:30 PM
More...
|
Mologen AG (MOLGF.PK): Promising Start to 2012 Business Year - Quarterly Report Submitted
5/15/2012 11:42:03 AM
More...
|
Mologen AG (MOLGF.PK) -- Excellent Outcome for Phase 2 Colorectal Cancer Study With MGN1703 -- Primary Endpoint Achieved
5/14/2012 10:39:16 AM
More...
|
Mologen AG (MOLGF.PK) Attains the Goals of the Renal Cancer Study With MGN1601 Ahead of Schedule
11/21/2011 10:21:28 AM
More...
|
Mologen AG (MOLGF.PK) Will Next Clinically Investigate the Efficacy of MGN1703 in Lung Cancer
6/7/2011 9:46:12 AM
More...
|
Mologen AG (MOLGF.PK): Cell-Based Gene Therapy against Cancer (MGN1601) Granted Patent Protection in Europe
2/23/2011 10:29:24 AM
More...
|
Mologen AG (MOLGF.PK): A Further Clinical Study has Currently been Started - a New Therapy Approach for the Treatment of Renal Cancer
12/14/2010 10:47:43 AM
More...
|
Mologen AG (MOLGF.PK): Clinical Phase II/III Study for the Colorectal Cancer Medicine MGN1703 Launched
11/11/2010 12:44:57 PM
More...
|
Mologen AG (MOLGF.PK) - Clarification Process about the Product License was Positively Concluded as Expected - Arbitration Court Claim was Rejected
11/1/2010 2:20:58 PM
More...
|
|